JP2017501201A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501201A5
JP2017501201A5 JP2016544368A JP2016544368A JP2017501201A5 JP 2017501201 A5 JP2017501201 A5 JP 2017501201A5 JP 2016544368 A JP2016544368 A JP 2016544368A JP 2016544368 A JP2016544368 A JP 2016544368A JP 2017501201 A5 JP2017501201 A5 JP 2017501201A5
Authority
JP
Japan
Prior art keywords
pharmaceutical
parts
pharmaceutical composition
composition according
diluents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016544368A
Other languages
English (en)
Japanese (ja)
Other versions
JP6588915B2 (ja
JP2017501201A (ja
Filing date
Publication date
Priority claimed from GBGB1400034.3A external-priority patent/GB201400034D0/en
Application filed filed Critical
Publication of JP2017501201A publication Critical patent/JP2017501201A/ja
Publication of JP2017501201A5 publication Critical patent/JP2017501201A5/ja
Application granted granted Critical
Publication of JP6588915B2 publication Critical patent/JP6588915B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2016544368A 2014-01-02 2015-01-02 Ａｚｄ９２９１を含む医薬組成物 Active JP6588915B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1400034.3 2014-01-02
GBGB1400034.3A GB201400034D0 (en) 2014-01-02 2014-01-02 Pharmaceutical Compositions comprising AZD9291
PCT/GB2015/050001 WO2015101791A1 (en) 2014-01-02 2015-01-02 Pharmaceutical compositions comprising azd9291

Publications (3)

Publication Number Publication Date
JP2017501201A JP2017501201A (ja) 2017-01-12
JP2017501201A5 true JP2017501201A5 (enExample) 2018-02-08
JP6588915B2 JP6588915B2 (ja) 2019-10-09

Family

ID=50191689

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016544368A Active JP6588915B2 (ja) 2014-01-02 2015-01-02 Ａｚｄ９２９１を含む医薬組成物

Country Status (37)

Country Link
US (6) US10183020B2 (enExample)
EP (1) EP3089741B1 (enExample)
JP (1) JP6588915B2 (enExample)
KR (1) KR102336378B1 (enExample)
CN (2) CN114712362A (enExample)
AR (1) AR098989A1 (enExample)
AU (1) AU2015204218B2 (enExample)
CA (1) CA2933403C (enExample)
CL (1) CL2016001609A1 (enExample)
CR (1) CR20160310A (enExample)
CY (1) CY1124848T1 (enExample)
DK (1) DK3089741T3 (enExample)
DO (1) DOP2016000156A (enExample)
EA (1) EA034243B9 (enExample)
ES (1) ES2873226T3 (enExample)
GB (1) GB201400034D0 (enExample)
GT (1) GT201600142A (enExample)
HR (1) HRP20210749T1 (enExample)
HU (1) HUE054344T2 (enExample)
IL (1) IL246186B (enExample)
LT (1) LT3089741T (enExample)
MX (1) MX367358B (enExample)
MY (1) MY183536A (enExample)
NI (1) NI201600098A (enExample)
NZ (1) NZ721298A (enExample)
PE (1) PE20161170A1 (enExample)
PH (1) PH12016501310B1 (enExample)
PL (1) PL3089741T3 (enExample)
PT (1) PT3089741T (enExample)
RS (1) RS61927B1 (enExample)
SG (1) SG11201605339QA (enExample)
SI (1) SI3089741T1 (enExample)
SM (1) SMT202100330T1 (enExample)
TW (1) TWI702953B (enExample)
UY (1) UY35933A (enExample)
WO (1) WO2015101791A1 (enExample)
ZA (1) ZA201605300B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (enExample) 2014-01-24 2018-02-24
US10513509B2 (en) 2016-05-26 2019-12-24 Recurium Ip Holdings, Llc EGFR inhibitor compounds
CN108057036B (zh) * 2016-11-07 2023-06-13 正大天晴药业集团股份有限公司 一种egfr抑制剂的固体药物组合物
CN107176954B (zh) * 2017-06-02 2019-01-11 无锡双良生物科技有限公司 一种egfr抑制剂的药用盐及其晶型、制备方法和应用
CN110013468B (zh) * 2018-01-09 2022-02-18 北京福元医药股份有限公司 一种azd9291氘代衍生物药物制剂
WO2019138346A1 (en) * 2018-01-10 2019-07-18 Alembic Pharmaceuticals Limited Pharmaceutical composition of osimertinib
MA51823A (fr) * 2018-02-12 2021-05-19 Astrazeneca Ab Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules
HRP20250115T1 (hr) * 2018-03-01 2025-05-23 Astrazeneca Ab Farmaceutski pripravci koji sadrže (2s)-{(1s)-1-cijano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil} -1,4-oksazepan-2-karboksamid
EP3769764B1 (en) * 2018-03-23 2024-10-30 Wuxi Shuangliang Biotechnology Co., Ltd. Pharmaceutical composition and preparation method therefor and uses thereof
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
CN113645976A (zh) 2019-03-29 2021-11-12 阿斯利康(瑞典)有限公司 用于治疗非小细胞肺癌的奧希替尼
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2021148396A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
TW202304457A (zh) * 2021-03-22 2023-02-01 瑞典商阿斯特捷利康公司 配製物
AU2023246862A1 (en) 2022-03-31 2024-10-31 Astrazeneca Ab Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
IL317733A (en) 2022-06-27 2025-02-01 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for cancer treatment
CN119654152A (zh) 2022-07-08 2025-03-18 阿斯利康(瑞典)有限公司 与hgf-受体抑制剂组合用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
WO2025092926A1 (zh) * 2023-10-31 2025-05-08 浙江同源康医药股份有限公司 一种嘧啶类衍生物的药物组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110376A (en) * 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
WO2001076565A1 (fr) * 2000-04-12 2001-10-18 Banyu Pharmaceutical Co., Ltd. Compositions et preparations se desintegrant dans la cavite buccale
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
RU2318518C2 (ru) 2002-02-26 2008-03-10 Астразенека Аб Фармацевтическая композиция, обладающая антипролиферативным действием (варианты), способ ее получения и способы с ее использованием
US20080102133A1 (en) * 2004-10-05 2008-05-01 Antje Brueck-Scheffler Oral Pharmaceutical Preparation for Proton Pump Antagonists
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
BRPI0707671A2 (pt) * 2006-02-09 2011-05-10 Daiichi Sankyo Co Ltd composiÇço farmacÊutica anti-cÂncer
JP5576922B2 (ja) * 2006-04-20 2014-08-20 信越化学工業株式会社 腸溶性固体分散体を含んでなる固形製剤
AU2008274941A1 (en) * 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
EP2696857A1 (en) 2011-04-11 2014-02-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising bosentan
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
EP3333161B1 (en) * 2011-07-27 2020-02-19 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer
CA2860973C (en) * 2012-01-13 2021-10-26 Xspray Microparticles Ab A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component.
WO2013160916A1 (en) 2012-04-25 2013-10-31 Hetero Research Foundation Sunitinib malate solid dispersion
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291

Similar Documents

Publication Publication Date Title
JP2017501201A5 (enExample)
JP6588915B2 (ja) Ａｚｄ９２９１を含む医薬組成物
JP7269227B2 (ja) ニラパリブ処方物
CN109906077B (zh) 依达拉奉与(+)-2-莰醇的舌下用药物组合物
BRPI0908340A2 (pt) composição farmacêutica para fármacos pouco solúveis
EP2073791B1 (en) Capecitabine pediatric tablets
JPWO2014157137A1 (ja) シロドシンの苦味をマスキングした経口投与製剤
ES2856347T3 (es) Comprimido desintegrante oralmente recubierto con película
JP2012512142A (ja) カペシタビン速崩壊性錠剤
US20220331305A1 (en) Pharmaceutical Compositions Comprising Alpelisib
Venkateswarlu et al. Formulation and in vitro evaluation of orlistat orodispersible tablets for enhancement of dissolution rate
ES2674811T3 (es) Composiciones estables de fesoterodina
JP2020203874A (ja) ロキソプロフェン又はその塩とカノコソウとを含有する経口用医薬組成物
AU2007284644B2 (en) Compositions and methods for increasing blood platelet levels in humans
JP2023158069A (ja) ロキソプロフェン又はその塩及びビタミンｂ１２類を含有する経口用医薬組成物
US20170128482A1 (en) Modified release pharmaceutical compositions of sofosbuvir and ribavirin
JP2020169152A (ja) ロキソプロフェン又はその塩とボタンピとを含有する経口医薬組成物
EP2959888A1 (en) A novel pharmaceutical composition of sofosbuvir and ribavirin
Garg et al. FORMULATION AND EVALUATION OF ORO DISPERSIBLE TABLETS OF GLIBENCLAMIDE
Medarametla et al. Development of Ondansetron Tablets with Advanced Disintegrant Technology for Rapid Release and Improved Pharmacokinetics
JP2007284394A (ja) 被覆固形製剤
Helen Sonia et al. FORMULATION DEVELOPMENT AND EVALUATION OF TASTE MASKED CEFUROXIME AXETIL DISPERSIBLE TABLETS BY INCLUSION COMPLEXATION WITH β-CYCLODEXTRIN METHOD
WO2013137441A1 (ja) 経口医薬組成物
HK1170673B (en) Compositions and methods for increasing blood platelet levels in humans